MASCO CORP /DE/
MASCO CORP /DE/ (MAS) Stock News
The latest MAS headlines and market coverage — 3 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026
Altimmune announced 48-week data from its IMPACT Phase 2b trial showing that pemvidutide, a glucagon/GLP-1 dual receptor agonist, significantly reduced triglycerides (-23.7%), total cholesterol (-15.4%), and improved weight loss (7.5%), blood pressure, and waist circumference in MASH patients. The drug demonstrated a favorable safety profile with minimal discontinuations due to adverse events. The company plans to initiate the PERFORMA Phase 3 trial in the second half of 2026.
- GlobeNewswire Inc.·
Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis
Galectin Therapeutics presented new data from its NAVIGATE trial at EASL 2026 showing that belapectin 2 mg/kg demonstrated statistically significant reduction in new varices development at 18 months (p=0.04) and improvements in liver stiffness in patients with advanced MASH cirrhosis. The poster presentation on portal hypertension risk reduction was designated a TOP Poster at the conference. These findings support belapectin's potential as a disease-modifying therapy, with no currently approved alternatives available for this indication.
- Yahoo Finance·Bullish
Market Update: CCI, BA, BYD, NEE, INTC, LRCX, MAS, NOK, ROP